| Literature DB >> 21477664 |
Adam J Schwarz1, Lino Becerra, Jaymin Upadhyay, Julie Anderson, Richard Baumgartner, Alexander Coimbra, Jeff Evelhoch, Richard Hargreaves, Brigitte Robertson, Smriti Iyengar, Johannes Tauscher, David Bleakman, David Borsook.
Abstract
Functional magnetic resonance imaging (fMRI) experiments are more complex compared with standard radiological imaging, involving additional data streams and hardware along with complex analysis methods. Here, we propose guidelines based around mitigating risks associated with the complexities of the technique at the level of the individual imaging protocol, including workable and effective quality assurance/quality control procedures and rigorous, predefined, analysis pipelines. Our aim is to provide a framework for 'good imaging practice' (GIP), enabling these requirements to be addressed at an appropriate level of detail. The development of a procedural framework for GIP in pharmaceutical fMRI studies could lead to greater acceptance of the method within industry and facilitate validation and, eventually, qualification of the technique as an imaging biomarker.Mesh:
Substances:
Year: 2011 PMID: 21477664 DOI: 10.1016/j.drudis.2011.03.011
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851